CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 65 enrolled
Drug / intervention
Lotrafilcon A contact lens +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01379768
NCT01379768N/ACompleted
CompareCT.gov

Polymorphonuclear Leukocyte Response During Overnight Lens Wear

CIBA VISION·interventional·Posted Jun 23, 2011·Updated Mar 8, 2013

In Brief

A clinical study evaluating Lotrafilcon A contact lens, Lotrafilcon B contact lens, and 1 other intervention for White Blood Cells. Completed, enrolled 65 participants across 1 site.

Detailed Summary

The purpose of this study was to count and analyze the white blood cells in tear samples collected from study participants following sleep. The results from contact lens wearers were compared with the results from non-contact lens wearers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWhite Blood Cells
CountriesCanada
CollaboratorsUniversity of Waterloo

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 23, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.0 years ago

Interventions

Lotrafilcon A contact lensdevice

Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.

Lotrafilcon B contact lensdevice

Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.

Clear Care Cleaning and Disinfection Solutiondevice

Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses